References
- Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267–1278. doi:10.1016/S0140-6736(05)67394-1
- Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438–445. doi:10.1016/j.jacc.2006.04.070
- Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–714. doi:10.1016/0002-9343(77)90874-9
- Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 1981;141(9):1128–1131. doi:10.1001/archinte.1981.00340090024008
- Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15. doi:10.1161/01.cir.79.1.8
- Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(2):352–360; e2. doi:10.1016/j.ahj.2008.09.022
- Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370(9603):1907–1914. doi:10.1016/S0140-6736(07)61813-3
- Cannon CP, Dansky HM, Davidson M, et al. Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158(4):513–519; e3. doi:10.1016/j.ahj.2009.07.028
- Martin LJ, Connelly PW, Nancoo D, et al. Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apoprotein E genotype. J Lipid Res. 1993;34:437–446. doi:10.1016/S0022-2275(20)40735-7
- Radeau T, Lau P, Robb M, et al. Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J Lipid Res. 1995;36:2552–2561. doi:10.1016/S0022-2275(20)41091-0
- Antonio MG Jr, Christopher PC, Xiujiang SL, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113:76–83. doi:10.1016/j.amjcard.2013.08.041
- Georgy H, Sanjeev K, Douglas J, et al. Disposition into adipose tissue determines accumulation and elimination kinetics of the cholesteryl ester transfer protein inhibitor anacetrapib in mice. Drug Metab Dispos. 2016;44(3):428–434. doi:10.1124/dmd.115.067736
- Krishna R, Gheyas F, Liu Y, et al. Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther. 2017;102(5):832–840. doi:10.1002/cpt.700
- Chavez-Eng CM, Lutz RW, Li H, et al. Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1011:204–214. doi:10.1016/j.jchromb.2015.12.053